Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Ascendia Pharmaceuticals.

    Client Virtual Booth

    ASCENDIA PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Ascendia Pharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    675 US Highway One, North Brunswick, NJ 08902
    Telephone
    Telephone
    (732) 640-0058
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ascendiapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ascendia-pharmaceuticals-llc
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201

    Details:

    Under the agreement, Ascendia will provide services to support the clinical development of OA-201, a novel, injectable small molecule therapeutic for the treatment of symptomatic osteoarthritis pain.


    Lead Product(s): OA-201

    Therapeutic Area: Musculoskeletal Product Name: OA-201

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Ampio Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement October 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel that Received IND Approval

    Details:

    ASD-002 (clopidogrel) being developed by EmulSol nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval for Acute Coronary Syndrome.


    Lead Product(s): Clopidogrel

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: ASD-002

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: AcuteBio

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 23, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search